References
- ManchikantiLSinghATherapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioidsPain Physician2008112 SupplS638818443641
- PassikSDHaysLEisnerNKirshKLPsychiatric and pain characteristics of prescription drug abusers entering drug rehabilitationJ Pain Palliat Care Pharmacother200620251316702131
- ChouRFanciulloGJFinePGClinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain200910211313019187889
- TrescotAMHelmSHansenHOpioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians’ (ASIPP) GuidelinesPain Physician2008112 SupplS56218443640
- OPANA® ER (oxymorphone hydrochloride extended-release tablets)Full Prescribing InformationChadds Ford, PAEndo Pharmaceuticals Inc2008
- AdamsMPAhdiehHPharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover studyPharmacotherapy200424446847615098800
- FiskeWJobesJXiangQChangSBenedekIThe effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tabletsJ Pain2011 In press
- US Department of Health and Human ServicesGuidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations Available at: http://www.fda.gov/downloads/Durgs/Guidancecomplianceregulatoryinformation/guidances/ucm070124.pdfAccessed October 29, 2010
- HaleMEAhdiehHMaTRauckREfficacy and safety of Opana ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled studyJ Pain20078217518417145204
- KatzNRauckRAhdiehHA 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back painCurr Med Res Opin200723111712817257473
- GabrailNYDvergstenCAhdiehHEstablishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled studyCurr Med Res Opin200420691191815200750
- SlatkinNERhinerMIGouldEMMaTAhdiehHLong-term tolerability and effectiveness of oxymorphone extended release in patients with cancerJ Opioid Manag20106318119120642247
- KivitzAMaCAhdiehHGalerBSA 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or kneeClin Ther200628335236416750450
- McIlwainHAhdiehHSafety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year studyAm J Ther200512210611215767827
- SmithHSOpioid metabolismMayo Clin Proc200984761362419567715
- ConeEJCaplanYHUrine toxicology testing in chronic pain managementPostgrad Med200912149110219641275